• Revenue up 30% to £2 749m; up 15% compared to pro forma FY16 revenue including Al Noor (£2 391m)
  • Underlying EBITDA up 17% to £501m; underlying EBITDA margin decreased to 18.2% from 20.4%
  • Operating profit up 26% to £362m
  • Underlying earnings per share down 19% to 29.8 pence
  • In constant currency, revenue and underlying EBITDA increased by 15% and 3% respectively
  • Cash flow conversion at 101% of underlying EBITDA
  • Total dividend of 7.90 pence per share; in line with dividend policy


  • Hirslanden revenue up 3% to CHF1 704m; underlying EBITDA up 5% to CHF340m; underlying EBITDA margin of 20.0%
  • Southern Africa revenue up 7% to ZAR14 367m; underlying EBITDA up 6% to ZAR3 049m; underlying EBITDA margin of 21.2%
  • Middle East revenue up 72% to AED3 109m; revenue down 8% versus pro forma for the Al Noor combination; underlying EBITDA down 5% to AED364m; underlying EBITDA margin of 11.7%
* IFRS measure
** Non-IFRS measure

See the reconciliations between the statutory and underlying (non-IFRS) measures in the Financial Review.

Key Performance Indicators

1 The Group uses underlying income statement reporting as non-IFRS measures in evaluating performance and as a method to provide shareholders with clear and consistent reporting. See the reconciliations between the statutory and the non-IFRS measures in the Financial Review.
2 Earnings refer to profit attributable to equity holders.
3 The total dividend per share for the year ended 31 March 2017 in British pound comprises the proposed final dividend of 4.70 pence per share (2016: 5.24 pence) and the interim dividend of 3.20 pence per share, paid in December 2016 (2016: 2.66 pence).

Group results are subject to movements in foreign currency exchange rates. Refer to Financial Review for exchange rates used to convert the operating platforms’ results to pound sterling.

* The corporate social investment of Mediclinic Southern Africa excludes the significant financial support to academic institutions in the amount of R9.7m (2016: R8.0m) during the year.
** The environmental data of Mediclinic Southern Africa and Mediclinic Middle East is for the 2016 calendar year, while the comparative data is for the financial year ended 31 March 2016. The environmental data relating to Hirslanden was also reported on a calendar year basis in previous reports.